BioScience Health Innovations, Inc.
BHICDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
GBP510 adjuvanted with AS03
COVID-19
GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)
Covid19
GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1
COVID-19 (Healthy Volunteers)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GBP510 adjuvanted with AS03 | Phase 3 | COVID-19 | - | - |
GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose) | Phase 3 | Covid19 | - | - |
GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1 | Phase 2 | COVID-19 (Healthy Volunteers) | - | - |
Frequently asked questions
What is in BioScience Health Innovations, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in BioScience Health Innovations, Inc.'s (BHIC) pipeline across Phase 3, Phase 2. Its lead program is GBP510 adjuvanted with AS03 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioScience Health Innovations, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BioScience Health Innovations, Inc. (BHIC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BHIC biotech catalysts?→
Add BHIC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioScience Health Innovations, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.